SEC EDGAR · company profile · free

AbbVie Inc. due diligence

Who AbbVie Inc. (ABBV) is on the public record: identity, annual results, what it filed in the last year and why, straight from SEC EDGAR.

1001 filings in EDGAR's recent index, 570 of them Form 4 insider filings · view the filings on SEC EDGAR · source: SEC EDGAR submissions index and XBRL financial data

At a glance

AbbVie Inc. (ABBV) is a large accelerated filer incorporated in Delaware, classified under SIC 2834 (Pharmaceutical Preparations), and lists on NYSE. Its fiscal year ends December 31.

For the fiscal year ended December 31, 2025, its 10-K reported revenue of $61.2B, up 8.6% from the year before, net income of $4.2B, and total assets of $134B.

In the twelve months to October 9, 2026 it made 82 filings on EDGAR, including 1 annual report, 3 quarterly reports, 15 current reports on Form 8-K, and 42 Form 4 insider filings, plus 7 prospectus supplements and free writing prospectuses for its securities offerings. Its 8-Ks were filed most often for results of operations (8), other events (4), and Regulation FD disclosures (2).

CIK
0001551152
Filer status
Large accelerated filer
Industry (SIC)
Pharmaceutical Preparations (2834)
Incorporated
Delaware
Listed on
NYSE
Tickers
ABBV
Fiscal year end
12-31

Annual results

Fiscal year endedRevenueNet incomeTotal assets
2025-12-31$61.2B +8.6%$4.2B -1.2%$134B
2024-12-31$56.3B +3.7%$4.3B -12.0%$135B
2023-12-31$54.3B$4.9B$135B
As reported in each 10-K's XBRL data on SEC EDGAR (revenue tag RevenueFromContractWithCustomerExcludingAssessedTax); a later 10-K's restatement replaces the earlier figure.
FilingFiledPeriodAccession
Annual report (10-K)2026-02-202025-12-310001551152-26-000008
Quarterly report (10-Q)2026-08-032026-06-300001551152-26-000026
Current report (8-K)2026-10-052026-10-050001551152-26-000030

Filing activity

82 filings since 2025-10-09, 7 of them prospectus supplements and free writing prospectuses (not listed below). By form:

4
42
8-K
15
144
5
10-Q
3
10-K
1
11-K
1
4/A
1
ARS
1

8-K items in the last 12 months: results of operations (Item 2.02, 8) · other events (Item 8.01, 4) · Regulation FD disclosures (Item 7.01, 2) · shareholder vote results (Item 5.07, 1).

FiledFormDocumentPeriod
2026-10-058-K8-K2026-10-05
2026-10-024Form 4 insider filing2026-09-30
2026-10-024Form 4 insider filing2026-09-30
2026-09-038-KFORM 8-K2026-09-03
2026-08-184Form 4 insider filing2026-08-14
2026-08-188-KFORM 8-K2026-08-18
2026-08-14144Form 144 notice of proposed sale
2026-08-058-KFORM 8-K2026-08-04
2026-08-0310-Q10-Q2026-06-30
2026-07-318-K8-K2026-07-31
free alert

Free. One email a day at most, only when something changes. Confirm by email first; unsubscribe with one click. Privacy.

The full due-diligence dossier on AbbVie Inc.

The free view above is identity and filing dates. The paid dossier reads the filings: business and segments, financial trend, insider and institutional activity, litigation and risk-factor themes, recent news, and the red flags, every claim cited and delivered with a data appendix.

agents: POST /v1/dossier with {"ticker":"ABBV"} over x402 or MPP, $0.85

Sample output and API docs · all reports

ABBV insider filingsAll company profiles13F fund holdingsAll reports

Generated from public SEC EDGAR filings. Filing data is shown as filed. This is information, not investment advice.